|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0018801,
umls-concept:C0025859,
umls-concept:C0030685,
umls-concept:C0034785,
umls-concept:C0162621,
umls-concept:C0231449,
umls-concept:C0391871,
umls-concept:C0680255,
umls-concept:C0868939,
umls-concept:C0871261,
umls-concept:C1283071,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C1963578,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-2-28
|
|
pubmed:abstractText |
beta-Blockers require careful initiation and titration when used in patients with heart failure. Some patients tolerate beta-blocker therapy initiation without difficulty, whereas in other patients this period presents clinical challenges. We tested the hypothesis that polymorphisms at codons 389 (Arg389Gly) and 49 (Ser49Gly) of the beta(1)-adrenergic receptor would be associated with differences in initial tolerability of beta-blocker therapy in patients with heart failure. We also tested whether polymorphisms in the beta(2)-adrenergic receptor, G-protein alpha s subunit (G(s)alpha), and cytochrome P450 (CYP) 2D6 genes or S-metoprolol plasma concentrations were associated with beta-blocker tolerability.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
pubmed-author:AdamsKirkwood FKF,
pubmed-author:ArandaJuan MJM,
pubmed-author:BelgadoBernadette SBS,
pubmed-author:GelfandCraig ACA,
pubmed-author:HamiltonKaren KKK,
pubmed-author:HillJames AJA,
pubmed-author:JohnsonJulie AJA,
pubmed-author:LeeCraig RCR,
pubmed-author:PattersonJ HerbertJH,
pubmed-author:PaulyDaniel FDF,
pubmed-author:PhillipsMichael SMS,
pubmed-author:SchofieldRichard SRS,
pubmed-author:TerraSteven GSG,
pubmed-author:WalkerJoseph RJR,
pubmed-author:YarandiHossein NHN
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-37
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15735607-Cytochrome P-450 CYP2D6,
pubmed-meshheading:15735607-Delayed-Action Preparations,
pubmed-meshheading:15735607-Drug Administration Schedule,
pubmed-meshheading:15735607-Drug Resistance,
pubmed-meshheading:15735607-Exercise Tolerance,
pubmed-meshheading:15735607-GTP-Binding Protein alpha Subunits, Gs,
pubmed-meshheading:15735607-Genotype,
pubmed-meshheading:15735607-Heart Failure,
pubmed-meshheading:15735607-Humans,
pubmed-meshheading:15735607-Male,
pubmed-meshheading:15735607-Metoprolol,
pubmed-meshheading:15735607-Middle Aged,
pubmed-meshheading:15735607-Pharmacogenetics,
pubmed-meshheading:15735607-Phenotype,
pubmed-meshheading:15735607-Polymorphism, Genetic,
pubmed-meshheading:15735607-Receptors, Adrenergic, beta,
pubmed-meshheading:15735607-Time and Motion Studies,
pubmed-meshheading:15735607-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
|
|
pubmed:affiliation |
Department of Pharmacy Practice, University of Florida, Gainsville, FL 32610, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
